Therapeutics News and Research

RSS

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Acorda Therapeutics, Inc. announced data from a preclinical study showed that treatment with Glial Growth Factor 2 (GGF2) improved erectile function in an animal model following a cavernous nerve (CN) injury, a common complication of prostate surgery.

29 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Altheus Therapeutics announced today it has randomized its first patient in a comparator-controlled Phase 2 efficacy study of Zoenasa, a novel combination therapy for ulcerative colitis (UC).

29 Aug 2012

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM therapeutic, the first treatment developed utilizing its iSPERSE inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.

28 Aug 2012

Understanding photoreceptor proteins could lead to cancer drug therapy

How does a plant know when to sprout a leaf, fold its petals or bloom? Why do humans experience jet lag after a trip abroad?

24 Aug 2012

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Novira Therapeutics Inc. today announced it has secured $23 million in Series A financing to support the development of its capsid-targeting antivirals for the treatment of chronic hepatitis B (HBV) and HIV infections.

24 Aug 2012

Dartmouth’s professor shares news of DAR-901 TB vaccine development

Tuberculosis (TB) is second only to HIV/AIDS as the greatest killer worldwide attributable to a single infectious agent, according to the World Health Organization (WHO). With 8.8 million cases in 2010 and 95 percent of TB deaths occurring in low- and middle-income countries, the disease continues to be a major public health problem in the developing world. In a July address to the International Union Against Tuberculosis and Lung Disease, Dartmouth's C. Fordham (Ford) von Reyn shared news of a promising vaccine in the works.

24 Aug 2012

McGill University experts to present at World Cancer Congress

The following list includes some of the McGill University experts who will be attending or presenting at the World Cancer Congress (WCC), the largest gathering of international leaders in the field of cancer, taking place in Montreal from August 27 to 30, 2012.

24 Aug 2012

Influenza virus can change microRNA expression to control immune responses in human lung cells

When you are hit with the flu, you know it immediately -- fever, chills, sore throat, aching muscles, fatigue. This is your body mounting an immune response to the invading virus. But less is known about what is happening on the molecular level.

24 Aug 2012

Agenda now available for Transcatheter Cardiovascular Therapeutics symposium

TCT 2012 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation will provide significant clinical research updates to technologies and practices in interventional cardiology that will directly affect patient care.

23 Aug 2012

Proteonomix enters license agreement for new anti-tumor technology

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has entered into an exclusive worldwide license agreement for a novel source of primary human cells that secrete a factor capable of inhibiting tumor cell growth and causing tumor cell death.

23 Aug 2012

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, and collaborators at Radboud University Nijmegen Medical Centre in the Netherlands announced today that they have published new pre-clinical results in the journal Cancer Immunology Immunotherapy describing the development of a dendritic cell (DC) cancer vaccine with enhanced immunogenic potential.

23 Aug 2012

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

The hematology journal BLOOD published today a full-length article describing final Phase 2 data for Symphogen's rozrolimupab, a novel human recombinant mixture of 25 antibodies which all are manufactured simultaneously from a single batch.

22 Aug 2012

FDA committee to review NPS’ Gattex NDA in October

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing therapeutics for rare gastrointestinal and endocrine disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that its New Drug Application (NDA) for Gattex (teduglutide) will be discussed at the Gastrointestinal Drugs Advisory Committee meeting scheduled for October 16, 2012.

22 Aug 2012

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial.

20 Aug 2012

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.

17 Aug 2012

Radiosensitivity molecular signature can lead to better radiation therapy decisions for breast cancer

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

16 Aug 2012

Low adropin levels may increase risk of metabolic disease

Working with a national team of researchers, a scientist from the Florida campus of The Scripps Research Institute has shown for the first time a link between low levels of a specific hormone and increased risk of metabolic disease in humans.

16 Aug 2012

3SBio files APX001 IND application with SFDA in China

Apexigen, Inc., an emerging biopharmaceutical company focused on the discovery and development of monoclonal antibody therapeutics, announced today that its partner, 3SBio [SSRX] of Shenyang, China, filed an Investigational New Drug (IND) application for APX001, also known as SSS07, with the State Food and Drug Administration (SFDA) in China.

16 Aug 2012

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121.

15 Aug 2012

Therapeutics News and Research

Acorda’s GGF2 can improve erectile function after cavernous nerve damage

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Altheus Therapeutics initiates enrollment in Zoenasa Phase 2 study for ulcerative colitis

Three Pulmatrix PUR118 clinical studies on COPD, asthma to be presented at ERS Annual Congress

Understanding photoreceptor proteins could lead to cancer drug therapy

Novira secures $23M in Series A financing to support antiviral development for HBV, HIV

Dartmouth’s professor shares news of DAR-901 TB vaccine development

McGill University experts to present at World Cancer Congress

Influenza virus can change microRNA expression to control immune responses in human lung cells

Agenda now available for Transcatheter Cardiovascular Therapeutics symposium

Proteonomix enters license agreement for new anti-tumor technology

New results describe development of DC cancer vaccine with enhanced immunogenic potential

Final data from Symphogen's rozrolimupab Phase 2 trial on primary immune thrombocytopenia

FDA committee to review NPS’ Gattex NDA in October

Juventas commences treatment in JVS-100 Phase II STOP-HF trial for late stage heart failure

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Radiosensitivity molecular signature can lead to better radiation therapy decisions for breast cancer

Low adropin levels may increase risk of metabolic disease

3SBio files APX001 IND application with SFDA in China

Proteonomix receives FDA approval to commence UMK-121 Phase 1 trial in end-stage liver disease

Event guide: The Non-Opioid Pain Therapeutics Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News